Caris Diagnostics devises gene test for colon cancer patients

Phoenix-based Caris Diagnostics has developed a genetic test that can help identify colon cancer patients most likely to benefit from treatment with chemotherapy in tandem with tailored cancer drugs, such as ImClone Systems' Erbitux and Amgen's Vectibix. The combination of a test and a targeted medication shows the potential of personalized therapies in drug delivery, Caris CEO Dr. Robert Penny said.

View Full Article in:

Arizona Republic (Phoenix) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX